^
    4d
    Chimeric Antigen Receptor-T Cell Therapy for Pediatric and Young Adult Primary Central Nervous System Tumors: A Systematic Review of Early Phase Clinical Trials with a Focus on Diffuse Midline Glioma. (PubMed, Target Oncol)
    Preliminary clinical experience indicates that CAR-T cell therapy for pediatric and young adult CNS tumors is biologically active and clinically feasible, exhibiting a distinct yet manageable toxicity profile. Although durable objective responses are currently limited, the frequent occurrence of disease stabilization and extended survival in certain patients substantiate ongoing research and the refinement of CAR-T cell strategies for CNS malignancies.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR806-specific CAR T-cell therapy
    7ms
    Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors (clinicaltrials.gov)
    P1, N=72, Active, not recruiting, Seattle Children's Hospital | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR806-specific CAR T-cell therapy • SC-CAR4BRAIN
    7ms
    STRIvE-01: EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (clinicaltrials.gov)
    P1, N=44, Active, not recruiting, Seattle Children's Hospital | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2025 --> Jun 2040
    Enrollment closed • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    EGFR806-specific CAR T-cell therapy • SCRI-CARB7H3(s)x19
    1year
    DENALI-1: A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression (clinicaltrials.gov)
    P1/2, N=240, Recruiting, A2 Biotherapeutics Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    over1year
    Locoregional Infusion of EGFR806-CAR T Cells for Recurrent or Refractory Pediatric CNS Tumors: Results of the Completed BrainChild02 Phase 1 Clinical Trial. (PubMed, Neuro Oncol)
    Intracranially infused EGFR806-CAR T cells were tolerable at tested doses, with a best response of stable disease. EGFR is a potentially useful target for cellular therapy against pediatric brain tumors, particularly high-grade gliomas.
    P1 data • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR expression • EGFR wild-type
    |
    EGFR806-specific CAR T-cell therapy • depatuxizumab (ABT-806)
    over1year
    EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors (clinicaltrials.gov)
    P1, N=11, Completed, Seattle Children's Hospital | Active, not recruiting --> Completed | Trial completion date: Mar 2040 --> Dec 2023 | Trial primary completion date: Mar 2025 --> Dec 2023
    Trial completion • Trial completion date • Trial primary completion date • CAR T-Cell Therapy • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR positive
    |
    EGFR806-specific CAR T-cell therapy
    over1year
    The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM (clinicaltrials.gov)
    P1, N=50, Enrolling by invitation, Shanghai Simnova Biotechnology Co.,Ltd.
    New P1 trial • CAR T-Cell Therapy
    |
    SNC109
    almost2years
    GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers (clinicaltrials.gov)
    P1, N=30, Recruiting, Second Affiliated Hospital of Guangzhou Medical University | Trial completion date: Aug 2026 --> Aug 2036 | Trial primary completion date: Aug 2024 --> Aug 2026
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18) • AXL (AXL Receptor Tyrosine Kinase) • MSLN (Mesothelin) • CD276 (CD276 Molecule) • GPC3 (Glypican 3) • TGFB1 (Transforming Growth Factor Beta 1) • GUCY2C (Guanylate Cyclase 2C) • PSCA (Prostate Stem Cell Antigen 2)
    |
    GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells
    almost2years
    Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC (clinicaltrials.gov)
    P1, N=11, Recruiting, Second Affiliated Hospital of Guangzhou Medical University | Trial primary completion date: Nov 2024 --> Nov 2029
    Trial primary completion date • CAR T-Cell Therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • CXCL13 (Chemokine (C-X-C motif) ligand 13)
    almost2years
    EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, Second Affiliated Hospital of Guangzhou Medical University | Trial completion date: May 2025 --> May 2035 | Trial primary completion date: May 2025 --> May 2030
    Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • CD276 (CD276 Molecule)
    |
    Undisclosed EGFR/B7H3 CAR-T
    2years
    STRIvE-01: EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (clinicaltrials.gov)
    P1, N=44, Recruiting, Seattle Children's Hospital | Trial completion date: Jun 2038 --> Jun 2040 | Trial primary completion date: Jun 2024 --> Jun 2025
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    EGFR806-specific CAR T-cell therapy • SCRI-CARB7H3(s)x19
    over2years
    The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=16, Recruiting, Shanghai Simnova Biotechnology Co.,Ltd. | Trial primary completion date: Aug 2023 --> May 2024
    Trial primary completion date • CAR T-Cell Therapy
    |
    SNC109